查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726286

全球免疫測量市場：市場規模、佔有率、趨勢分析（按產品、應用、最終用途和地區）、細分市場預測（2025-2030 年）

Radioimmunoassay Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Kits), By Application (Research, Clinical Diagnostics), By End Use (Hospitals, Laboratory), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 320 Pages | 商品交期: 2-10個工作天內

價格

免疫測量市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球免疫測量市場規模預計到2030年將達到17.9億美元，2025年至2030年期間的複合年成長率為2.93%。

市場成長背後的驅動力是 RIA 在敏感和特異性診斷應用中的重要角色。儘管新的免疫測量技術不斷湧現，RIA 仍然是檢測微量荷爾蒙、藥物、腫瘤標記和傳染性病原體的主要解決方案。主要的市場驅動力是全球慢性病和感染疾病的增加。根據聯合國愛滋病規劃署估計，到 2023 年，全球愛滋病毒感染者人數將接近 3,990 萬人，新增感染人數為 130 萬人，反映出對放射免疫分析 (RIA) 等準確可靠的檢測方法的持續需求。此外，甲狀腺疾病和某些癌症的盛行率不斷上升，推動了對精確內分泌和腫瘤診斷的需求。

RIA 技術和試劑的最新進展也促進了市場的成長。 Medipan GmbH 等公司正在延長 TSH、Tg 和抑鈣素RIA套件的保存期限，從而提高實驗室效率。此外，該公司於 2022 年推出的簡化 SELco TRAb 一步檢測法縮短了甲狀腺抗體檢測的周轉時間並簡化了工作流程。策略聯盟和收購進一步凸顯了市場整合和創新。例如，DiaSorin 對 Luminex Corporation 的收購擴大了其多重測試能力並加強了其在包括 RIA 在內的專業診斷領域的地位。此外，DIAsource 與 Svar Life Science（前身為 Euro Diagnostica）達成的里程碑協議將支持先進免疫檢測解決方案的開發，進一步支持 RIA 技術的廣泛應用。

免疫測量市場也受到其與臨床診斷和研究的相關性的影響。在臨床環境中，尤其是醫院和診斷實驗室，RIA 常規用於荷爾蒙測量和過敏測試，因此佔據了相當大的市場佔有率。然而，利用 RIA 的高特異性進行生物醫學研究的實驗室正在推動最快的成長。 LabLogic 系統和自動伽馬計數器等先進分析儀器的引入支持了 RIA 工作流程的現代化，並擴大了對高通量應用程式的存取。

實驗室晶片(LOC) 技術的進步徹底改變了傳統的免疫測量(RIA)。微流體免疫分析平台（μ-RIA）的開發已顯著縮短分析時間至約 5 分鐘，並最大限度地減少了試劑消費量。這些改進解決了 RIA 先前的局限性，例如較長的​​孵育時間和放射性廢棄物的產生，並增強了該技術在臨床診斷中的適用性。這些發展凸顯了為改善放射性標記和免疫測量方法以及提高診斷影像和標靶診斷的準確性、效率和安全性而做出的共同努力。近日，2025年3月，亞伯達大學的研究人員宣布了一項新的分子影像測試，將單株抗體Panitumumab與放射性同位素銅-64結合。Panitumumab針對的是表皮生長因子受體（EGFR），該受體在非小細胞肺癌細胞中通常過度表現。當用銅-64標記時，這種結合物可以實現精確的 PET 成像，從而有助於早期發現和監測肺癌。這種混合方法為傳統切片檢查提供了一種非侵入性的替代方法，並可以透過​​及時干預來改善患者的預後。

免疫測量市場：概述

  • 按產品分類，試劑和套件將在 2024 年收益佔有率。內分泌、腫瘤學、感染疾病和自體免疫疾病檢測對可靠診斷工具的需求不斷成長，推動了實驗室和醫院對 RIA 試劑和試劑套件的消費量大幅增加。這些套件通常含有放射性標記的抗原或抗體（通常用碘-125）、緩衝液、標準品和分離試劑。由於其高靈敏度和特異性，這些套件對於臨床實驗室檢測 TSH、胰島素、皮質醇、睪固酮和雌二醇等荷爾蒙至關重要。例如，PerkinElmer 和 DIAsource ImmunoAssays 提供多種用於甲狀腺功能測試（例如 TSH 和抑鈣素）、不孕激素和腫瘤標記的 RIA套件，以支持常規篩檢和專門診斷。另一方面，分析儀器預計將成為預測期內成長最快的領域。
  • 從 2024 年免疫測量產業應用來看，由於 RIA 技術在常規和專門的醫學檢測中的廣泛應用，臨床診斷將以 76.33% 的以收益為準佔有率領先於該行業。這項優勢主要歸功於該技術在檢測微量生物標記濃度方面具有出色的靈敏度和特異性，對於準確診斷、疾病監測和治療計劃具有重要意義。預計該研究領域在預測期內將成長最快。
  • 由於醫院擁有全面的診斷能力，且需要準確檢測生物標記的疾病日益流行，醫院在 2024 年佔據終端市場主導地位，收入佔有率達 32.54%。 RIA 具有出色的靈敏度和特異性，因此在醫院環境中，它對於準確測量患者樣本中的低濃度荷爾蒙、藥物和其他物質至關重要。此外，醫院採用自動化和先進的 RIA 系統簡化了工作流程、縮短了周轉時間並提高了結果的準確性。
  • 全球免疫測量市場以北美為主，2024 年的收入佔有率為 47.43%。成長動力包括先進的醫療保健基礎設施、積極的研發 (R&D) 活動以及需要精確診斷工具的慢性病的高盛行率。此外，支持性政策和報銷框架正在促進 RIA 在臨床診斷中的採用和整合。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章放射免疫測量市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 市場機會分析
    • 供應鏈分析
    • 分銷管道
  • 免疫測量市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析
  • 醫療費用報銷概述
  • 定價分析

第4章免疫測量市場：按產品分類的估計和趨勢分析

  • 細分儀表板
  • 免疫測量市場：變異分析（按產品分類）（2024 年和 2030 年）
  • 分析器
  • 試劑和套件

第5章免疫測量市場：按應用的估計和趨勢分析

  • 細分儀表板
  • 免疫測量市場：變異分析，依應用（2024 年和 2030 年）
  • 研究
  • 臨床診斷

第6章免疫測量市場：依最終用途的估計和趨勢分析

  • 細分儀表板
  • 免疫測量市場：變異分析，依最終用途分類（2024 年和 2030 年）
  • 醫院
  • 臨床診斷實驗室
  • 製藥業
  • 其他

第7章：免疫測量市場：區域估計與趨勢分析

  • 免疫測量市場佔有率（按地區分類）（2024 年和 2030 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 全球公司市場佔有率分析（2024年）
  • 公司熱圖分析
  • 戰略地圖
    • 擴張
    • 企業合併與收購（M&A）
    • 夥伴關係和合作
    • 新產品發布
    • 研究與開發
  • 公司簡介
    • DIAsource
    • Tecan Trading AG
    • PerkinElmer
    • DRG International Inc.
    • Oxford BioSystems
    • DiaSorin SpA
    • Eurodiagnostico, SL
    • MP Biomedicals
    • Merck KGaA
Product Code: GVR-4-68040-554-8

Radioimmunoassay Market Growth & Trends:

The global radioimmunoassay market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 2.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.

Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin's acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.

The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA's high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.

Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.

Radioimmunoassay Market Report Highlights:

  • The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
  • The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method's exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
  • The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals' comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
  • North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
  • 1.7. Details of primary research
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
      • 1.9.1.1. Approach 1: Commodity flow approach
    • 1.9.2. Volume price analysis (Model 2)
      • 1.9.2.1. Approach 2: Volume price analysis
  • 1.10. Research Scope and Assumptions
    • 1.10.1. List of Secondary Sources
    • 1.10.2. List of Primary Sources
    • 1.10.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rising Prevalence 0f Chronic and Infectious Diseases
      • 3.2.1.2. High Sensitivity and Specificity of RIA Techniques
      • 3.2.1.3. Advancements in Radiolabeled Reagents and Assay Technologies
      • 3.2.1.4. The Rising Amount of Blood Donations in Blood Banks
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. Presence of Ambiguous Regulatory Framework
      • 3.2.2.2. High Cost of RIA Equipment
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Supply Chain Analysis
    • 3.2.5. Distribution Channel
      • 3.2.5.1. Direct Sales
      • 3.2.5.2. Distributors Network
      • 3.2.5.3. E-commerce and Online Platforms
      • 3.2.5.4. Major Distributors
  • 3.3. Radioimmunoassay Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Legal landscape
  • 3.4. Reimbursement Overview
  • 3.5. Pricing Analysis

Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Radioimmunoassay Market: Product Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Analyzers
    • 4.3.1. Analyzers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Reagents and Kits
    • 4.4.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Radioimmunoassay Market: Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Research
    • 5.3.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Clinical Diagnostics
    • 5.4.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Radioimmunoassay Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Clinical Diagnostics Laboratories
    • 6.4.1. Clinical Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Pharmaceutical Industries
    • 6.5.1. Pharmaceutical Industries Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis

  • 7.1. Radioimmunoassay Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.2.2.3. Competitive Insights
      • 7.2.2.4. U.S. Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.2.3.3. Competitive Insights
      • 7.2.3.4. Canada Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.2.4.3. Competitive Insights
      • 7.2.4.4. Mexico Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.2.3. Competitive Insights
      • 7.3.2.4. UK Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.3.3. Competitive Insights
      • 7.3.3.4. Germany Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.4.3. Competitive Insights
      • 7.3.4.4. France Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.5.3. Competitive Insights
      • 7.3.5.4. Italy Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.6.3. Competitive Insights
      • 7.3.6.4. Spain Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.7.3. Competitive Insights
      • 7.3.7.4. Sweden Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Denmark
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.8.3. Competitive Insights
      • 7.3.8.4. Denmark Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.9.3. Competitive Insights
      • 7.3.9.4. Norway Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. China Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Japan Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. India Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.5.3. Competitive Insights
      • 7.4.5.4. South Korea Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.6.3. Competitive Insights
      • 7.4.6.4. Australia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.7.3. Competitive Insights
      • 7.4.7.4. Thailand Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. Brazil Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Argentina Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Saudi Arabia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. UAE Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. South Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Kuwait Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Global Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research And Development
  • 8.6. Company Profiles
    • 8.6.1. DIAsource
      • 8.6.1.1. Participant's Overview
      • 8.6.1.2. Financial Performance
      • 8.6.1.3. Product Benchmarking
      • 8.6.1.4. Recent Developments
    • 8.6.2. Tecan Trading AG
      • 8.6.2.1. Participant's Overview
      • 8.6.2.2. Financial Performance
      • 8.6.2.3. Product Benchmarking
      • 8.6.2.4. Recent Developments
    • 8.6.3. PerkinElmer
      • 8.6.3.1. Participant's Overview
      • 8.6.3.2. Financial Performance
      • 8.6.3.3. Product Benchmarking
      • 8.6.3.4. Recent Developments
    • 8.6.4. DRG International Inc.
      • 8.6.4.1. Participant's Overview
      • 8.6.4.2. Financial Performance
      • 8.6.4.3. Product Benchmarking
      • 8.6.4.4. Recent Developments
    • 8.6.5. Oxford BioSystems
      • 8.6.5.1. Participant's Overview
      • 8.6.5.2. Financial Performance
      • 8.6.5.3. Product Benchmarking
      • 8.6.5.4. Recent Developments
    • 8.6.6. DiaSorin S.p.A.
      • 8.6.6.1. Participant's Overview
      • 8.6.6.2. Financial Performance
      • 8.6.6.3. Product Benchmarking
      • 8.6.6.4. Recent Developments
    • 8.6.7. Eurodiagnostico, S.L.
      • 8.6.7.1. Participant's Overview
      • 8.6.7.2. Financial Performance
      • 8.6.7.3. Product Benchmarking
      • 8.6.7.4. Recent Developments
    • 8.6.8. MP Biomedicals
      • 8.6.8.1. Participant's Overview
      • 8.6.8.2. Financial Performance
      • 8.6.8.3. Product Benchmarking
      • 8.6.8.4. Recent Developments
    • 8.6.9. Merck KGaA
      • 8.6.9.1. Participant's Overview
      • 8.6.9.2. Financial Performance
      • 8.6.9.3. Product Benchmarking
      • 8.6.9.4. Recent Developments

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Mexico radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 13 Mexico radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 14 Mexico radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 18 Europe radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Germany radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 20 Germany radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 23 UK radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 24 UK radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 25 France radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 26 France radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 27 France radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Italy radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 29 Italy radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 30 Italy radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Spain radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 32 Spain radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 33 Spain radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Denmark radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 35 Denmark radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 36 Denmark radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Sweden radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 38 Sweden radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 39 Sweden radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Norway radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 41 Norway radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 42 Norway radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 48 China radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 49 China radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Japan radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 51 Japan radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 52 Japan radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 53 India radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 54 India radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 55 India radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 56 South Korea radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 57 South Korea radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 58 South Korea radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Australia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 60 Australia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 61 Australia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Thailand radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 63 Thailand radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 64 Thailand radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 66 Latin America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Brazil radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 69 Brazil radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 70 Brazil radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Argentina radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 72 Argentina radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 74 MEA radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Africa radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 84 UAE radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait radioimmunoassay market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Radioimmunoassay market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Parent market outlook, 2024
  • Fig. 10 Radioimmunoassay market driver impact
  • Fig. 11 Radioimmunoassay market restraint impact
  • Fig. 12 Market entry strategy
  • Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Radioimmunoassay market: Product outlook and key takeaways
  • Fig. 16 Radioimmunoassay market: Products movement analysis
  • Fig. 17 Analyzers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Reagents and kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Radioimmunoassay market: Application outlook and key takeaways
  • Fig. 20 Radioimmunoassay market: Application movement analysis
  • Fig. 21 Research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Radioimmunoassay market: End use outlook and key takeaways
  • Fig. 24 Radioimmunoassay market: End use movement analysis
  • Fig. 25 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical diagnostics laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Pharmaceutical industries market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Radioimmunoassay Market: Regional outlook and key takeaways
  • Fig. 30 Radioimmunoassay market: Regional movement analysis
  • Fig. 31 North America
  • Fig. 32 North America. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. key country dynamics
  • Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Canada key country dynamics
  • Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico key country dynamics
  • Fig. 38 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Europe
  • Fig. 40 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 UK key country dynamics
  • Fig. 42 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Germany key country dynamics
  • Fig. 44 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Spain key country dynamics
  • Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 France key country dynamics
  • Fig. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Italy key country dynamics
  • Fig. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark key country dynamics
  • Fig. 52 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden key country dynamics
  • Fig. 54 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Norway key country dynamics
  • Fig. 56 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific
  • Fig. 58 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Japan key country dynamics
  • Fig. 60 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea key country dynamics
  • Fig. 66 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America
  • Fig. 72 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Brazil key country dynamics
  • Fig. 74 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina key country dynamics
  • Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 MEA
  • Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 UAE key country dynamics
  • Fig. 82 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)